648 related articles for article (PubMed ID: 15928338)
1. Slowing progression along the renal disease continuum.
Kopyt NP
J Am Osteopath Assoc; 2005 Apr; 105(4):207-15. PubMed ID: 15928338
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
3. [Control of arterial pressure in diabetic nephropathy].
Luño J; García de Vinuesa S
Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
[No Abstract] [Full Text] [Related]
4. [Prediction, screening and treatment of renal complications of diabetes].
Marre M; Larger E
Rev Prat; 2001 Oct; 51(16):1769-75. PubMed ID: 11795120
[TBL] [Abstract][Full Text] [Related]
5. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
[TBL] [Abstract][Full Text] [Related]
6. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
de Zeeuw D
Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
[TBL] [Abstract][Full Text] [Related]
7. [Microalbuminuria is an early marker for increased morbidity and mortality].
Bramlage P; Wittchen HU; Pittrow D; Dikow R; Kirch W; Lehnert H; Ritz E
Fortschr Med Orig; 2003 Feb; 121 Suppl 1():28-32. PubMed ID: 14732947
[TBL] [Abstract][Full Text] [Related]
8. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
Dussol B; Berland Y
Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
[TBL] [Abstract][Full Text] [Related]
9. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?
Schmieder RE
J Hypertens Suppl; 2006 Apr; 24(2):S31-5. PubMed ID: 16601559
[TBL] [Abstract][Full Text] [Related]
10. Microalbuminuria and cardiovascular risk.
Karalliedde J; Viberti G
Am J Hypertens; 2004 Oct; 17(10):986-93. PubMed ID: 15485765
[TBL] [Abstract][Full Text] [Related]
11. Improving microvascular outcomes in patients with diabetes through management of hypertension.
McGill JB
Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
Cantarovich F; Rangoonwala B
Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
[TBL] [Abstract][Full Text] [Related]
13. Microalbuminuria, insulin resistance, diabetes, hypertension, and kidney function: the latest concepts in pathology and pharmacologic treatment.
Barri YM; Palmer BF; Ram CV
Postgrad Med; 2005 Dec; 118(6 Suppl Beta-Blockers):34-45. PubMed ID: 19667709
[TBL] [Abstract][Full Text] [Related]
14. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes.
Donnelly R; Yeung JM; Manning G
J Hypertens Suppl; 2003 Mar; 21(1):S7-12. PubMed ID: 12769161
[TBL] [Abstract][Full Text] [Related]
15. Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians.
Bakris GL; Kuritzky L
Postgrad Med; 2009 Jul; 121(4):51-60. PubMed ID: 19641270
[TBL] [Abstract][Full Text] [Related]
16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
17. [Clinical studies on chronic diabetic nephropathy and recent data concerning prevention of risks of nephropathy and cardiovascular diseases].
Esnault V
Nephrol Ther; 2006 May; 2 Suppl 3():S193-6. PubMed ID: 17370850
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum.
Chrysant SG
Clin Ther; 2008; 30 Pt 2():2181-90. PubMed ID: 19281913
[TBL] [Abstract][Full Text] [Related]
19. Diabetic nephropathy: common questions.
Thorp ML
Am Fam Physician; 2005 Jul; 72(1):96-9. PubMed ID: 16035688
[TBL] [Abstract][Full Text] [Related]
20. The role of angiotensin receptor blockers in diabetic nephropathy.
Sharma AM; Weir MR
Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
